Kunstone Biotech Secures Tens of Millions in Pre-A+ Funding to Advance Engineered CAR-Macrophage Therapies and Lead Pipeline RR-M01 Toward IND Submission

Mar 11, 2025 12:05 CST Updated 12:05

Rock Roc Biotechnology

Macrophage Chimeric Antigen Receptor Therapy Developer

ROC ROCK Biotechnology Successfully Completes Pre-A+ Round Financing Worth Tens of Millions of RMB, Exclusively Invested by Qingdao Yinghai Antai Equity Investment Partnership (Limited Partnership). The funds from this round will accelerate the clinical trials and commercialization processes of multiple products, injecting strong momentum into the company's future development.

Previously, the company successfully completed an angel round of financing led by DS Capital and a Pre-A round of financing led by Huizhu Medical, with cumulative financing reaching nearly 100 million yuan, demonstrating the high recognition of ROC ROCK Biotechnology by the capital market.

ROC ROCK Biotechnology, founded in 2021, is a clinical-stage company focused on the research and development of macrophage-based drugs for cancer and chronic diseases. It is also the world’s only company with an engineered macrophage technology platform driven by the integration of live cell factors, gene editing, biomaterials, and synthetic biology. The company has been honored with several prestigious titles, including National High-tech Enterprise, Key Leading Talent in Science and Technology of Suzhou Industrial Park, Science and Technology Small and Medium-sized Enterprise, Innovative Small and Medium-sized Enterprise, and Jiangsu Privately-run Science and Technology Enterprise. Additionally, it undertakes national-level "Challenge Leader" technical research projects.

Since its establishment, ROC ROCK Biotechnology has focused on the development and clinical application of macrophage-based drugs for treating cancer and chronic diseases, actively advancing the research and industrialization of Chimeric Antigen Receptor Macrophages (CAR-M). It has established a preparation facility meeting GMP standards with cleanliness laboratory specifications (B+A) in Suzhou Industrial Park, and is collaborating with multiple institutions globally to advance nine CAR-M cell drug pipelines through multi-center cooperation.

Four Self-developed Technology Platforms Propel Multiple Pipelines into Clinical Research

ROC ROCK Biotechnology has accumulated extensive experience in macrophage engineering, bioinformatics analysis, and immune cell transdifferentiation. It has mastered several key CAR-M technologies, including engineered macrophage modification, CAR design, and viral vector modification, overcoming the challenge of difficult macrophage transduction. The company is making continuous breakthroughs in the field of innovative therapies for solid tumors and steadily advancing multiple important pipelines.

Lead Pipeline Achieves Major Breakthrough, IND Filing in 2025

ROC ROCK Biotechnology's Leading Pipeline RR-M01 Injection is an innovative drug meticulously developed for solid tumors. Its creation stems from the research team's in-depth study and relentless exploration of cancer pathogenesis. Through a unique mechanism of action, RR-M01 Injection has the potential to precisely target cancer cells, inhibiting their growth and spread while minimizing damage to normal cells.